A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
After a conference lacking the wow factor, biotech winners and losers emerge.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.